We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01734798
First Posted: November 28, 2012
Last Update Posted: November 28, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mohamed s. Zaghloul, Cairo University
  Purpose
Radical Cystectomy is still the standard treatment in muscle-invasive Bladder cancer. Local recurrence is still the major cause of failure together with distant metastasis. postoperative radiotherapy succeeded to decrease the local recurrence and hence improved the overall survival. Adjuvant chemotherapy has also improved the survival in different studies. This study is performed to test the efficacy and toxicity of adding the two modalities together compared to each modality alone.

Condition Intervention Phase
Locally Advanced Bladder Cancer Radiation: Radiation Drug: gemcitabine and cisplatin Other: Radiotherapy and Drug Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Resource links provided by NLM:


Further study details as provided by Mohamed s. Zaghloul, Cairo University:

Primary Outcome Measures:
  • Comparison of the disease-free survival and overall survival of post-operative radiotherapy , adjuvant chemotherapy and the combined modalities [radiotherapy and chemotherapy] after radical cystectomy [ Time Frame: Five-year overall and disease-free survival. ]
    Regular follow up is performed every 2 months in the first 2 years postcystectomy and every 6 months thereafter. Periodical CT pelvis is performed every 6 months in the first 2 years and yearly thereafter. The other appropriate radiological studies are performed in response to patients' symptoms and signs. Treatment side effects (immediate and late) are reported in each follow up visit.


Secondary Outcome Measures:
  • comparison of the Local recurrence rate in the three Arms [ Time Frame: Five year local pelvic control rate ]
    Periodical CT pelvis is performed every 6 months in the first 2 years and yearly thereafter. The other appropriate radiological studies are performed in response to patients' symptoms and signs. Treatment side effects (immediate and late) are reported in each follow up visit.


Enrollment: 198
Study Start Date: December 2002
Study Completion Date: November 2012
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
Radiation: Radiation
Experimental: Arm 2
adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
Other: Radiotherapy and Drug
Experimental: Arm 3
Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
Drug: gemcitabine and cisplatin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients not more than 70 years old.
  • Radical cystectomy performed within 42 days with no microscopic or macroscopic residual after surgery (negative surgical safety margins)
  • Having one or more of the risk factors ( P3b,P4a,G3 and /or positive LN)
  • ECOG Performance Scale (0-2).
  • Adequate liver functions.
  • Adequate renal function serum (creatinine < 1.5 mg).
  • No evidence of distant metastasis or other malignancy.

Exclusion Criteria:

  • patients who received radiotherapy or chemotherapy prior to radical cystectomy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01734798


Locations
Egypt
National cancer Institute-Cairo University
Cairo, Egypt
Sponsors and Collaborators
Cairo University
  More Information

Responsible Party: Mohamed s. Zaghloul, Professor of Radiation Oncology, Cairo University
ClinicalTrials.gov Identifier: NCT01734798     History of Changes
Other Study ID Numbers: Bladder-02
First Submitted: November 19, 2012
First Posted: November 28, 2012
Last Update Posted: November 28, 2012
Last Verified: November 2012

Keywords provided by Mohamed s. Zaghloul, Cairo University:
locally advanced bladder cancer
Postoperative radiotherapy
Adjuvant chemotherapy
Radical Cystectomy

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Gemcitabine
Cisplatin
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs